For: | Salmerón Ríos S, Cortés Zamora EB, Avendaño Céspedes A, Romero Rizos L, Sánchez-Jurado PM, Sánchez-Nievas G, Mas Romero M, Tabernero Sahuquillo MT, Blas Señalada JJ, Murillo Romero A, García Nogueras I, Estrella Cazalla JD, Andrés-Pretel F, Lauschke VM, Stebbing J, Abizanda P. Immunogenicity after 6 months of BNT162b2 vaccination in frail or disabled nursing home residents: The COVID-A Study. J Am Geriatr Soc 2021. [PMID: 34894403 DOI: 10.1111/jgs.17620] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis] |
---|
Number | Citing Articles |
1 | Schiavoni I, Palmieri A, Olivetta E, Leone P, Di Lonardo A, Mazzoli A, Cafariello C, Malara A, Palamara AT, Incalzi RA, Onder G, Stefanelli P, Fedele G; GeroCovid Vax CMI Study Group. T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents. J Am Med Dir Assoc 2023;24:140-147.e2. [PMID: 36587928 DOI: 10.1016/j.jamda.2022.11.024] [Reference Citation Analysis] |
2 | Montejano-Hervás P, Gómez-Pavón J, Tornero-Torres O, Valverde-Moyar MV, Martín Cruz B, Vela Carbonera M, Fuentes-Irigoyen R, Tejada González P, González-Becerra M, Higueras Sánchez E, Ramos Cordero P. Safety, Effectiveness, and Immunogenicity 6 Months After BNT162B2 mRNA Vaccine in Frail Nursing Home Residents. Drugs Aging 2022. [PMID: 35794430 DOI: 10.1007/s40266-022-00959-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis] |